Maarso 2023: Xarunta Kansarka ee Peter MacCallum (Peter Mac) ee Australia iyo Cartherics Pty Ltd waxay galeen heshiis barnaamijka horumarinta iskaashiga ah (CDPA) si ay u horumariyaan CTH-002 ee daaweynta kansarka ugxan-sidaha.
Tijaabada caafimaad ee uu qabanayo Peter Mac waxay noqon doontaa markii ugu horeysay ee badeecada daawaynta unug ee CAR-T oo ay ku jiraan wax ka beddelka hidde-sidaha ee lagu dhex daray CTH-004 lagu tijaabiyo aadanaha.
Kansarka ugxan-sidaha waa kan ugu halista badan ee kansarka haweenka ee Australia, kaas oo gala in ka badan 1,000 qof sannadkii. Marka la eego heerka badbaadada shanta sano ee kaliya 49%, waxaa jirta baahi degdeg ah oo cilmi baaris ah si kuwa la ogaado la siiyo fursad wanaagsan oo ay ku badbaadaan.
Simon Harrison, maamulaha Xarunta Wanaajinta ee Cellular immunotherapy Peter Mac, wuxuu yiri: "CAR-T-cell therapy waa immunotherapy awood leh kaas oo si gaar ah loogu talagalay bukaan kasta oo dib-u-ujeedada u leh T-unugyadooda si ay ula dagaallamaan kansarkooda.
“It has emerged as a new treatment paradigm in kansarka dhiigga where it can produce complete responses, meaning their blood cancer has disappeared, in patients who have exhausted all other treatment options. The Centre of Excellence in Cellular Immunotherapy at Peter Mac is part of an international effort to expand CAR T-cell daaweynta oo ka baxsan kansarka dhiigga, waxaanan ku faraxsanahay inaan la kaashanno Cartherics tijaabadan caafimaad ee ugu horreysa ee bini'aadamka ee kansarka ugxan-sidaha.
Alan Trounson, CEO of Cartherics, said: “There are many patients needing help to control kansarka ugxansiduhu and CAR-T therapy could be a game changer for them. It is our priority to ensure this potential therapy is tested in tijaabada caafimaadka sida ugu dhaqsaha badan."
Cartherics board advisor, Heather Hawkins said: “As an ovarian ka badbaaday kansarka and patient advocate, I am truly grateful for the vision, skill and dedication of the Cartherics team who are working tirelessly – seeking to improve the survival rates and the quality of life of women diagnosed with ovarian cancer. This announcement brings a real sense of progress and hope in this space.”
In ka badan 80% bukaannada kansarka ugxan-sidaha ee markii hore lagu sameeyay qalliin lagu guuleystay iyo daawaynta waxay la kulmaan soo noqoshada.
Ujeedooyinka aasaasiga ah ee cilmi-baarista iskaashiga ayaa ah in la soo saaro CTH-004 ee qiyaasta bukaan-socodka iyo in la sameeyo tijaabada bukaan-socodka ee wajiga I. Barnaamijkan waxaa hogaamin doona Xarunta heer sare ee Immunotherapy Cellular ee Peter Mac, halka wax soo saarka ay fulin doonaan Peter Mac-hawlgalayaasha wax soo saarka, Cell Therapies Pty Ltd.
Tijaabada caafimaadku waxay bilawga diiwaan gelin doontaa lix ilaa laba iyo toban bukaan oo qaba kansarka ugxan-sidaha kuwaas oo daawadii hore ee kiimoterabigu ku guuldareystay. Ujeedada koowaad ee tijaabadan caafimaad waa in la qiimeeyo badbaadada CTH-004 ee dadka bukaanka ah.
Cartherics iyo Peter Mac ayaa dhawaan ku dhawaaqay iskaashi CTH-001, badeeco kale oo CAR-T autologous ah oo ay soo saartay Cartherics. La-hawlgalayaashu waxay ku heshiiyeen, iyadoo lagu saleynayo xogta saxda ah, in Peter Mac uu xoogga saari doono dadaalladeeda CTH-004.
Ku saabsan kansarka ugxan-sidaha
Ovarian cancer is a disease in which abnormal cell growth in one or both ovaries leads to the development of cancer. Approximately 314,000 new ovarian cancer cases and 207,000 deaths occurred globally in 2020.
Marxaladaha hore, kansarka ugxan-sidaha caadi ahaan asymptomatic ayaa lagu ogaadaa marxaladda dambe. Qalliinka iyo kiimoterabiga ayaa ah daawaynta ugu badan, ama kaligood ama isku-dar. In ka badan 80% bukaannada kansarka ugxan-sidaha ee markii hore lagu sameeyay qalliin lagu guuleystay iyo daawaynta waxay la kulmaan soo noqoshada.
Ku saabsan Xarunta Kansarka ee Peter MacCallum
Xarunta Kansarka ee Peter MacCallum waa cilmi baadhis heer caalami ah oo heer caalami ah, waxbarasho, iyo xarun daawaynta, iyo sidoo kale adeega caafimaadka guud ee Australiya oo si gaar ah ugu heellan daryeelka kansarka. Xaruntu waxa ka shaqeeya 3,300 oo qof, oo ay ku jiraan in ka badan 750 shaybaadhka iyo cilmi-baarayaasha caafimaadka, kuwaas oo dhamaantood u heellan inay bixiyaan daawaynta kansarka, daryeelka, iyo dawooyinka suurtagalka ah.
Xarunta heer sare ee Immunotherapy Cellular ee Peter Mac waxay taageertaa, horumarisaa, oo tarjumtaa daawaynta unugyada cusub iyo hiddo-wadaha iyadoo la adeegsanayo alaab-qeybiyeyaasheeda la aasaasay iyo la-hawlgalayaasheeda wax soo saarka, sida Cell Therapies Pty Ltd, si ay awood ugu siiso isticmaalka alaabooyinkan tijaabooyinka caafimaad ee bukaannada kansarka.
Intaa waxaa dheer, shirkaddu waxay abuurtaa autologous CAR-T daawaynta unugyada. Kuwani waxay ka faa'iidaystaan unugyada T-da ee laga beddelay habka difaaca bukaanka kuwaas oo waxtar u leh unugyada kansarka bukaanka. CTH-004 waxaa soo saara by genetically modified unugyada bukaanka T si ay u geliyaan a chimeric antigen reseptor (CAR) si ay u beegsadaan calaamade (TAG-72) on unugyada kansarka ugxan-sidaha iyo tirtirto hiddo ku lug leh xakamaynta shaqada unugyada T.
CAR T-Cell daaweynta Shiinaha waxa uu ku koray xawli aad u xowli badan, waxana hadda jira in ka badan 750 tijaabo caafimaad oo lagu sameeyo dalka Shiinaha oo ku saabsan noocyada kala duwan ee kansarka.
